usp chapter : updates for 2008 eric s. kastango, mba, rph, fashp clinical iq, llc florham park, nj,...
Post on 18-Dec-2015
222 views
TRANSCRIPT
![Page 1: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/1.jpg)
USP Chapter <797>: Updates for 2008
Eric S. Kastango, MBA, RPh, FASHP
Clinical IQ, LLC
Florham Park, NJ, USA
![Page 2: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/2.jpg)
Disclaimer
“Although I am a member of the USP Sterile Compounding Committee, I am speaking in my individual capacity and not as a member of the Committee or as a USP representative. The views and opinions presented are entirely my own. They do not necessarily reflect the views of USP, nor should they be construed as an official explanation or interpretation of <797>.”
![Page 3: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/3.jpg)
USP Chapter <797> Timeline
• Posted on USP website on December 3rd
– www.usp.org
• The General Chapter will become official via a Revised Bulletin with an official date of June 1, 2008
• It is “the” revised chapter based on 3 years of feedback and comments
• 2005-2010 USP SCC has no plans on revising the chapter again.
• Any changes will be driven by scientific evidence and will be taken up by the 2010-2015 USP SCC
![Page 4: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/4.jpg)
Members of the SCC Committee
• Chair - David Newton, Ph.D., R.Ph. • Vice Chair - Lawrence A. Trissel, R.Ph, FASHP
Members:
Samuel Augustine, Pharm. D.
Mary Baker, Pharm.D.
James F. Cooper, Pharm.D.
Donald Filibeck, Pharm.D
Larry Griffin, R.Ph.
Kenneth Hughes, R.Ph.
Eric S. Kastango, MBA, R.Ph.
Keith St. John, M.S.
Laura Thoma, Pharm. D.
James Wagner
Scientific Liaison:
Claudia C. Okeke, Ph.D., R.Ph.
![Page 5: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/5.jpg)
USP Advisory Groups
• Infection Control Advisory Committee
• Radiopharmaceutical Advisory Committee
• Allergen Extract Working Group
• Compounding Isolator Industry Round Table
• Food and Drug Administration
![Page 6: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/6.jpg)
Changes and Clarifications in <797>
• Introduction (Revised)
• Definitions section (new)
• Immediate-Use category (new)
• Low-Risk Level with 12 hour BUD (new)
• Single & multiple-dose containers (new)
• Proprietary vial/bag systems (new)
• Hazardous drugs (revised)
![Page 7: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/7.jpg)
Changes and Clarifications in <797>
• Radiopharmaceuticals (revised)• Allergen Extract CSPs (new)• Cleaning and disinfecting facilities (revised)• Personnel cleansing and garbing (revised)• Environmental controls (revised) • Environmental sampling (revised)
![Page 8: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/8.jpg)
Changes and Clarifications in <797>
• Filter integrity testing for High Risk Level compounding (new)
• Microbiological BUD (revised)
• “Shall vs. Should” Table (new)
• Clarified language throughout
(We hope!)
![Page 9: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/9.jpg)
Key to Understanding <797>:
Read Chapter <797>!!
![Page 10: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/10.jpg)
Introduction
• Complete revision to be more explicit• Acknowledges direct contact is the principal
source of contamination in CSPs • New robust Definitions section for 29 key terms• Alternative technologies proven equivalent or
superior to conventional work practices are OK• 797 applies to CSPs given via application,
implantation, inhalation, injection, insertion, instillation, and irrigation
![Page 11: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/11.jpg)
Responsibilities of Compounding Personnel in <797>
• 14 areas of responsibility are cited
• Emphasizes training and education
• Emphasizes compounding accuracy
• Emphasizes avoiding contamination
• Emphasizes patient safety
![Page 12: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/12.jpg)
CSP Risk Categories
• Immediate Use CSPs
• Low-Risk Level
• Low-Risk Level w/12 hour or less BUD
• Medium-Risk Level
• High-Risk Level
![Page 13: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/13.jpg)
Immediate-Use Category
• Exempt from all requirements in <797>
• Only simple aseptic measuring and transfer are needed
• NMT 3 sterile non-hazardous drugs
• No delays/interruptions
• No contact contamination of ingredients or critical sites
![Page 14: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/14.jpg)
Immediate-Use Category
• Dose must be labeled if not administered by the preparer
• Administration must begin within 1 hour after the start of preparation
• Dose must be discarded if administration has not begun within 1 hour after the start of preparation
(No storing. No recycling.)
![Page 15: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/15.jpg)
Immediate-Use Category
Intended applications:
• At a patient’s bedside
• In an ambulance, ED or during a “Code”
Unintended applications:
• Routine compounding:– Operating rooms, recovery areas– Physician offices
![Page 16: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/16.jpg)
Low-Risk Level CSPs
• Compounded from NMT 3 sterile commercial containers using commercial sterile devices
• Maintained in ISO Class 5 environment in an ISO 7 buffer area at all times
• Only a few basic, closed-system, simple aseptic transfers and manipulations
![Page 17: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/17.jpg)
Low-Risk Level w/12 hour BUD
• Low-Risk Level remains nearly the same • New subsection for an ISO 5 device in an
uncontrolled air environment• Must be in a segregated compounding area not
in a high traffic area-Satellite pharmacy• All personnel cleansing and garbing,
environmental sampling requirements apply• No Hazardous Drugs: “THINK CONTAINMENT”• Administration must begin within 12 hours or as
stated in the package insert, whichever is less
![Page 18: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/18.jpg)
Medium-Risk Level CSPs
• Four or more sterile commercial drug containers
• Multiple pooled sterile commercial products for multiple patients or one patient multiple times
• Complex aseptic manipulations– TPN, PCA
• Compounding requires long duration
![Page 19: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/19.jpg)
High-Risk Level CSPs
• Prepared from non-sterile ingredients• Preparation from sterile ingredients but
exposed to less than ISO Class 5• More than 6 hour delay from compounding to
sterilization• Purity of components is assumed but not
verified by documentation-C of A• Sterilization by filtration - the
manufacturer’s recommended integrity test MUST be performed on the filter– Bubble-Point
![Page 20: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/20.jpg)
Old Expired BUD Paradigm
• Assume the compounded preparation was sterile
• Historically based solely on the drug’s chemical stability
![Page 21: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/21.jpg)
Chapter<797> BUD Paradigm
• Recognizes the possibility that the CSP was inadvertently contaminated during compounding process
• For patient safety, BUD based on two factors:– Drug’s chemical stability in conjunction with
microbiological limits,
• BUD will always be whichever is shorter
![Page 22: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/22.jpg)
Calculated Microbial GrowthCundell AM, USP Committee on Analytical Microbiology,
Pharmacopeial Forum 2002; 28 (6) Stimuli to the Revision Process
Time (Hours) Microbial Count(CFU per mL)
6 10
9 640
12 41,000
18 1.7 X 107
24 6.9 X 109
![Page 23: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/23.jpg)
<797> Microbiological BUD
• There is an ever-present chance, indeed likelihood, that some CSPs will be inadvertently contaminated
• Time and warm temperatures are the enemy, speeding the potential for growth of dangerous amounts of microbial contamination
• Guidance for limits is needed to avoid unacceptable risks of harming patients
![Page 24: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/24.jpg)
Microbiological Beyond-Use Dating
Risk Category Room Temp Refrigerator Freezer
(-10 °C)
Immediate Use
1 hour 1 hour N/A
Low 48 hours 14 days 45 days
Low w/
12-hr BUD
12 hours or less
12 hours or less N/A
Medium 30 hours 9 days 45 days
High 24 hours 3 days 45 days
![Page 25: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/25.jpg)
Single/Multiple Dose Vials
• Definitions of SDV and MDV are in the USP General Notices and Requirements
• Single dose vials – Opened or punctured in ISO 5 environment may be used for up to 6 hours. Opened or punctured in worse than ISO 5 must be used within 1 hour or discarded.
• Single dose ampuls must be discarded after opening and not stored for any time period
![Page 26: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/26.jpg)
Single/Multiple Dose Vials
• Multiple dose vials – Contain antimicrobial preservative(s)
• Designed for entry on multiple occasions. BUD – 28 days after initial entry unless specified otherwise by the manufacturer.
• BUD of 28 days based on USP <51> Antimicrobial Preservative Testing
• Expiration date on vial is based on an unopened, properly stored vial.
![Page 27: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/27.jpg)
Proprietary Bag/Vial Systems
• ADD-Vantage; Add-a-Vial, Minibag Plus, etc.
• Follow the manufacturer’s instructions for handling and storing.
• These devices and their instructions have been approved by the FDA
• BUD ranges from 15 days to 10 weeks
![Page 28: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/28.jpg)
Hazardous Drugs
• Section extensively revised
• NIOSH Guidelines for guidance
• BSC or CACI required
• Hazardous drug storage and preparation in separate negative pressure ISO 7 with ISO 7 ante area
![Page 29: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/29.jpg)
Hazardous Drugs
• Personnel protection specified
• Use of closed-system transfer devices must be within BSC or CACI
• Disposal according to state and federal regulations
![Page 30: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/30.jpg)
Allergen Extracts
• Intradermal and subcutaneous MDVs and SDVs (No IV or IT)
• Unpreserved allergen extracts must fully comply with all aspects of <797>
• Allergen extracts are exempt from personnel, environment, and storage requirements only if all of the following criteria are met:
![Page 31: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/31.jpg)
Allergen Extracts
• Personnel perform hand hygiene with alcohol-based surgical hand scrub
• Hair and beard covers, gown, face mask, and sterile gloves are used
• Compounded by simple aseptic transfer• Must contain an effective amount of
antimicrobial preservative• For one patient only
![Page 32: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/32.jpg)
Allergen Extracts
• Collaboration with AAOA/JCAAI
• Research and discussions with experts in the field
• Results of a peer-reviewed research study of 26,795 injections (>98/patient) with no infections
• Done in an uncontrolled environment
![Page 33: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/33.jpg)
Cleaning and Disinfecting Facilities
• Based on Infection Control Advisory Committee recommendations
• Goal: Reduce bioburden in compounding areas • Use of disinfecting agent such as sterile 70%
IPA• Performed in ISO 5 environment:
1. At the beginning of each work shift2. At the beginning of each batch3. At least every 30 minutes
4. When surface contamination is known or suspected
![Page 34: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/34.jpg)
Cleaning and Disinfecting Facilities
• Cleaning should proceed from buffer area (cleanroom) to ante area
• Use suitable dedicated mops, etc. and disinfecting cleaners
• Floors, counters, work surfaces – at least daily
• Walls, ceilings, shelving – at least monthly
![Page 35: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/35.jpg)
Hand Hygiene
• USP Chapter <797> harmonized with CDC Guidelines for Hand Hygiene
• Hand washing is defined as the vigorous, brief (30 seconds) rubbing together of all surfaces of lathered hands, followed by rinsing under a stream of water.
• Hand washing suspends microorganisms and mechanically removes them by rinsing with water. The fundamental principle of hand washing is removal, not killing.
• Single most important way to reduce the risks of transmitting germs.
![Page 36: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/36.jpg)
Hand hygiene1 is paramount to safety, as this agar imprint of an unwashed hand shows2
1 http://www.cdc.gov/handhygiene/ 2 E Larson. Am J Nurs, AJN. July 1989: 935
![Page 37: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/37.jpg)
Personnel Cleansing and Garbing
• Remove outer garments and jewelry (including piercings above the neck)
• Garb order from dirtiest to cleanest• Don shoe covers, hair covers, face masks• Perform hand/arm hygiene • Don disposable gowns
![Page 38: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/38.jpg)
Personnel Cleansing and Garbing
• Inside the clean area, cleanse hands and arms with alcohol-based surgical hand scrub with persistent activity
• After hands and arms are dry, don sterile powder-free gloves compatible with sterile 70% IPA
• Repeatedly apply sterile 70% IPA to contact areas of gloves whenever nonsterile surfaces are touched (e.g. vials, counter tops, carts)
![Page 39: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/39.jpg)
Compounding Personnel
• Hair net• Beard cover and face
mask• Gown
– Nonsterile
• Gloves– Sterile
• Shoe covers
![Page 40: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/40.jpg)
Personnel Cleansing and Garbing
• All of the cleansing, garbing and gloving requirements also apply to compounding in CAIs and CACIs.
• Exception: If the manufacturer of the CAI or CACI provides written documentation of statistically validated testing supporting any garbing component(s) that are not required.
• Trust but “verify” claims made by vendors to ensure that all risks are understood
![Page 41: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/41.jpg)
ISO Class 5 Sources, Buffer Areas, and Ante Areas
![Page 42: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/42.jpg)
Environmental Controls
• Aimed at creating ISO 5, 7, and 8 environments• ISO 5 – LAFW, BSC, CAI, CACI are “Primary
Engineering Controls”• Must maintain ISO 5 during dynamic (in use)
working conditions• Unidirectional airflow required
![Page 43: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/43.jpg)
Environmental Controls
• ISO 7 buffer area and ISO 8 ante area – are “Secondary engineering controls”
• Must maintain ISO 7 or 8 during dynamic (in use) working conditions
• Airflow and balance testing required at the installation site
• Only personnel and materials essential for compounding and cleaning are permitted
![Page 44: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/44.jpg)
Environmental Controls
• ISO 5 Primary engineering control (LAFW, BSC, CAI, CACI) to be in an ISO 7 environment
• Exception: CAI if its design provides ISO 5 and isolation from the room during dynamic operating conditions as placed and tested at your site (including transferring materials in and out) using CETA testing
• Do your “Due Diligence” to verify the accuracy of any such claim
![Page 45: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/45.jpg)
Missing Research
• Paucity of independent research evaluations and comparisons of pharmacy applications of primary and secondary engineering controls.
• Unlike BSCs, CAIs and CACIs have not be tested independently
• CETA CAG-003-2006 is an important document to ensure consistent testing
![Page 46: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/46.jpg)
Environmental Sampling
Environmental Sampling Task• Dilemma:
– One of the most contentious section of USP Chapter <797>
– Since 1970’s, the US Centers for Disease Control (CDC) has not advocated routine viable environmental monitoring
– The US Food and Drug Administration requires sterile processing operations to perform daily monitoring of viable air, surface and personnel glove fingertip samples
![Page 47: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/47.jpg)
Environmental Sampling
None Daily
US Centers for Disease Control
Routine Viable Microbial Environmental Sampling (ES)
US Food and Drug Administration
![Page 48: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/48.jpg)
Environmental Sampling
None Daily
US Centers for Disease Control
Routine Viable Microbial Environmental Sampling (ES)
US Food and Drug Administration
USP 797
![Page 49: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/49.jpg)
Environmental Sampling
• Designed to demonstrate that the primary and secondary engineering controls, disinfecting procedures, and work practices result in a suitable environment for aseptic compounding
• Utilizes several approaches to assess and evaluate
![Page 50: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/50.jpg)
Environmental Sampling
• Environmental Sampling section has been separated into a facility-related performance metric and a personnel –related performance metric
• Facility-related Environmental Sampling– Viable air sampling via volumetric method (impaction) to occur at least
every 6 months
• Personnel-related Environmental Sampling – Personnel fingertip sampling during initial training, with media fills and
as a competency assessment tool – Surface sampling for viable microorganisms
![Page 51: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/51.jpg)
Environmental Monitoring • Viable Air Sampling
– Gravimetric vs. Volumetric Sampling
Courtesy of MSI, Inc. Houston, TX (www.microbiologyspecialists.com)
![Page 52: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/52.jpg)
Other Changes in <797>
• Radiopharmaceuticals quality assurance based on Advisory Committee recommendations
• Expanded explanatory and descriptive material in many sections
• Clarified language throughout
![Page 53: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/53.jpg)
Closing Thoughts
• USP Chapter <797> is about more than just cleanrooms and facilities– IT IS A QUALITY SYSTEM and PATIENT SAFETY
• Involves– Leadership (embrace evidence-based science and
best practices) even when its not convenient or inexpensive
– Properly educated and trained pharmacists and technicians
– Proper Employee Supervision and Feedback – Control of Critical Practices & Consistent Work
Practices– Documentation-NOT A PRACTICE IN FUTILITY
![Page 54: USP Chapter : Updates for 2008 Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ, USA](https://reader036.vdocuments.site/reader036/viewer/2022062515/56649d255503460f949fc0bd/html5/thumbnails/54.jpg)
Be mindful of your practices and remember there is someone who is loved by someone
receiving your CSP